LABT

Intravesical administration of the Bisphosphocin® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in a vehicle control group.SARASOTA, Fla., Oct. 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive preclinical data in urinary tract infection (UTI) and pulmonary infection indications in animal models treated with Bisphosphocin® compounds.In an animal model of UTI, intravesical administratio

SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City. He will also attend and present at the ThinkEquity Conference on October 15, 2026, in New York City. Later in the month, Dr. Cooper will present a poster on Nu-3 preclinical data at IDWeek on October 22, 2026

8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

Lead candidate Nu-3 is a topically formulated Bisphosphocin®, designed to rapidly kill microbes while reducing the risk of antimicrobial resistanceSARASOTA, Fla., Sept. 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being investigated in a Phase 2a clinical trial as a topical treatment of mildly infected diabetic foot ulcer

EFFECT - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platformTopline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatmen

Clinical and Corporate HighlightsSuccessfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolutionStrengthened balance sheet through completion of a $7.5 million private placement to support continued clinical advancementReported positive preclinical safety and tolerability data supporting dose selection for the upcoming Phase 2a clinical trial evaluating Nu-3 Gel in infected diabetic foot ulcers (iDFUs)Announced internationally recognized diabetic foot expert David G. Armstrong, DPM, MD, Ph.D., as Study Chair and Scientific Advisor for the Phase 2a clinical programExpanded global intellectual property portfolio with a n

S-1 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

SARASOTA, Fla., Sept. 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial evaluating the safety and efficacy of its lead product candidate, Nu-3, in patients with mildly infected diabetic foot ulcers (iDFU). "Together, these miles

SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City. Details of the presentation are as follows:Event:H.C. Wainwright 28th Annual Global Investment Con

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

10-Q - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

DEFA14A - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

DEF 14A - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

PRE 14A - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance.SARASOTA, Fla., July 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced resistance data for Nu-3 in alignment with the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB).

8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects.SARASOTA, Fla., July 15, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in its upcoming Phase 2a clinical trial. "These preclinical r

Company highlights its differentiated Bisphosphocin® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance developmentSARASOTA, Fla., July 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation designed to encourage the development of novel therapies t

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD

Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU programSARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has accepted the position of Study Chair for the Company's Phase 2a clinical trial evaluating Nu-3 for the treatment of infected diabe

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

New patent enhances global IP footprint and pipeline expansion opportunitiesSARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.